Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels

Cancer Chemotherapy and Pharmacology

Volumn 49, Issue 5, 2002, Pages 356-366

  Moog, R ^a   Burger, A ^a   Brandl, M ^b   Schuler J ^a   Schubert, R ^c   Unger, C ^a   Fiebig, H ^a   Massing, U ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Gemcitabine; Human tumor xenograft; Liposome; Metastases; Pharmacokinetics; Vesicular phospholipid gel; VPG

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; GEMCITABINE LIPOSOME CONJUGATE; LIPID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; CANCER INHIBITION; CANCER REGRESSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOLERABILITY; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SUSTAINED RELEASE FORMULATION; TUMOR XENOGRAFT;

EID: 0036232598     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-002-0428-4     Document Type: Article

References (39)

1. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A phase II study
2. Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes
3. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
4. Schedule-dependent antitumor effect of gemcitabine in in vivo model system
5. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts
6. Liposome preparation by a new high-pressure homogenizer Gaulin Micron Lab 40
7. Liposome preparation using high-pressure homogenizers
8. Three-dimensional liposome networks: Freeze fracture electron microscopical evaluation of their structure and in-vitro analysis of release of hydrophilic markers
9. Morphology of semisolid aqueous phosphatidylcholine dispersions, a freeze fracture electron microscopy study
10. Preparation and characterisation of semisolid phospholipid dispersions and dilutions thereof
11. Advanced breast cancer: A phase II trial with gemcitabine
12. Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection
13. Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
14. Phase I study of liposomal vincristine
15. Modified protocol for the testing of new synthetics in the lymphoid leukemia murine model in the DR&D program, DCT, NCI
16. Phase II study of liposomal doxorubicin in advanced gynecologic cancers
17. Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model
18. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
19. Liposomal formulations of anti-cancer drugs: Selectivity and effectiveness
20. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
21. Stability of lipid vesicles in tissues of the mouse: A gamma-ray perturbed angular correlation study
22. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study
23. Effect of nucleoside analogues and oligonucleotides on hydrolysis of liposomal phospholipids
24. Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer
25. Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes
26. Difluorodeoxycytidine (dFdC)-gemcitabine: A phase I study
27. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
28. Liposomal entrapment of floxuridine
29. A phase II study of gemcitabine (GEM) in bladder cancer (BC)
30. In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2′-deoxyuridine and its diacylated derivatives
31. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer
32. Pharmacological-toxicological expert report. CAELYX (Stealth liposomal doxorubicin HCl)
33. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes
34. UKCCCR guidelines for the welfare of animals in experimental neoplasia
35. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size